News and Insights
The latest news and insights from Genoa Healthcare.
- Clinical Insights
- Treatment
RELEXXII®: 6 things to know about the new FDA-approved treatment for ADHD
Staying on top of new medication options for your consumers living with ADHD can be difficult. Learn more about the new FDA-approved medication RELEXXII®, a long-acting formulation of methylphenidate. 1....
- Feb 11th, 2025
- Behavioral Health
- Clinical Insights
- Treatment
4 things to know about Spravato® (Intranasal esketamine)
On January 21, 2025, the FDA approved Spravato® nasal spray as the first and only monotherapy for adults living with TRD. The new label expansion will offer greater flexibility in...
- Jan 28th, 2025
- Behavioral Health
- Clinical Insights
- Treatment
Esketamine: Latest research offers new hope for adolescents with treatment-resistant depression
Adolescents with treatment-resistant depression (TRD) often struggle with a lack of effective treatment options. While ketamine has been shown to help improve outcomes for adults living with major depressive disorder...
- Jan 24th, 2025
- Behavioral Health
- Clinical Insights
- Partnering with Genoa
CMS reporting now required: 4 ways Genoa can help
By Reena Neumann, PharmD, MBA Since January 1, 2024, the Centers for Medicare & Medicaid Services (CMS) has required that clinics provide outcomes data reporting to secure federal funding through...
- Jan 15th, 2025
- Behavioral Health
- Clinical Insights
- Treatment
Brixadi®: 3 things to know about the buprenorphine treatment option
Staying on top of new medication therapy options for your consumers living with opioid use disorder (OUD) can be difficult. Learn how the new FDA-approved medication, Brixadi®, can help support...
- Oct 30th, 2024
- Behavioral Health
- Clinical Insights
- Treatment
Drug trends in behavioral health: What you need to know
Genoa Healthcare recently hosted a webinar where Pharmaceutical Program Manager Allie Butler, PharmD, and Clinical Pharmacist Cameron Yenney, PharmD, discussed the latest drug trends in behavioral health. Watch the recording...
- Oct 11th, 2024
- Behavioral Health
- Clinical Insights
- Treatment
Cobenfy™: 5 things to know about the new schizophrenia treatment option
Staying on top of new medication therapy options for your consumers living with schizophrenia can be difficult. Learn how the new FDA-approved medication, Cobenfy – approved on September 26, 2024...
- Oct 1st, 2024
- Clinical Insights
- HIV
- Treatment
Pharmacist-prescribed PrEP and PEP pilot expands pharmacy scope of practice
By Jennifer Finocchiaro, PharmD, AAHIVE The role of the pharmacist has changed significantly over the years, expanding from medication dispensing and counseling to providing direct patient care. As the pharmacy...
- Sep 10th, 2024
- Behavioral Health
- Clinical Insights
Caring for those with treatment-resistant depression
Genoa Healthcare® can partner with you to improve outcomes for your patients living with TRD. Connect with us to get started today. One in three adults with major depressive disorder...
- Aug 9th, 2024
- Behavioral Health
- Clinical Insights
- Treatment
Currently available and emerging therapy options for treatment-resistant depression
Studies show that 50% of people with major depressive disorder don’t respond adequately to initial antidepressant treatment.1 Additionally, an estimated 30% of people with major depressive disorder (MDD) experience treatment-resistant...
- Aug 2nd, 2024